Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.

Stock futures exhibited mixed performance on Tuesday as investors assessed fresh comments from President Donald Trump on ...

Hims stock plunged Tuesday after the compounding pharmacy issued a bullish outlook that still includes knockoff versions of ...

Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...

Hims & Hers, a leading health care platform, has been making waves with its impressive Q4 2024 earnings report. In a recent ...